Pembrolizumab With Carboplatin/Paclitaxel in Patients With Metastatic Melanoma
Status:
Active, not recruiting
Trial end date:
2025-12-01
Target enrollment:
Participant gender:
Summary
This is a multi-center, open-label, Phase II clinical trial evaluating pembrolizumab in
combination with carboplatin/paclitaxel as a treatment in unresectable locally advanced or
metastatic melanoma.